Trump said Israel has agreed a US-brokered ceasefire with Iran, boosting hopes for a more permanent end to their conflict.

I am initiating a 'sell' rating on Hims & Hers Health, with a fair value of $35 per share, due to imminent growth risks.

As voters head to the polls, the democratic socialist candidate appears to be neck-and-neck with Andrew Cuomo. That has many ...

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

A significant deal on weight loss drug collapsed in less than two months of its commitment, sparking a spat between Danish ...

Get CBS19 news on-demand by downloading the free CBS19+ app available on ROKU, Amazon Fire and Apple TV!

Novo Nordisk drops Hims & Hers because it was selling and promoting a cheaper copycat of Wegovy, its weight loss drug.

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.